Antibody-Targeted Photodynamic Therapy

Molecular and Cellular Therapeutics

Volumn , Issue , 2012, Pages 103-124

  Deonarain, Mahendra ^a   Stamati, Ioanna ^a   Yahioglu, Gokhan ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b PhotoBiotics Ltd   (United Kingdom)

Author keywords

Antibody targeted photodynamic therapy; Antibodydrug conjugate (ADC); Killer red; Photodynamic therapy (PDT); Photoimmunotherapy (PIT); Photosensitizers (PSs); Verteporfin

Indexed keywords

EID: 84876787198     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119967309.ch4     Document Type: Chapter

References (79)

1. Aggarwal, S. (2009) What's fueling the biotech engine-2008. Nat. Biotechnol., 27, 987-993.
2. Alley, S. C., Okeley, N. M. and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol., 14, 529-537.
3. Allison, B. A., Pritchard, P. H. and Levy, J. G. (1994) Evidence for low-density lipoprotein receptormediated uptake of benzoporphyrin derivative. Br. J. Cancer, 69, 833-839.
4. Allison, R. R. and Sibata, C. H. (2010) Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiag. Photodynam. Ther., 7, 61-75.
5. Alonso, C. M. A., Palumbo, A., Bullous, A. J., et al. (2010) Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies. Bioconj. Chem., 21, 302-313.
6. Ashur, I., Goldschmidt, R., Pinkas, I., et al. (2009) Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. J. Phys. Chem. A, 113, 8027-8037.
7. Babilas, P., Schreml, S., Landthaler, M. and Szeimies, R. M. (2010) Photodynamic therapy in dermatology: state-of-the-art. Photodermatol. Photoimmunol. Photomed., 26, 118-132.
8. Bhatti, M., Yahioglu, G., Milgrom, L. R., et al. (2008) Targeted photodynamic therapy with multiplyloaded recombinant antibody fragments. Int. J. Cancer, 122, 1155-1163.
9. Birchler, M., Viti, F., Zardi, L., et al. (1999) Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol., 17, 984-988.
10. Bonnett, R. (2000) Chemical Aspects of Photodynamic Therapy, 1st edn, Gordon and Breach Science (Publishers), London, UK.
11. Brown, S. B., Brown, E. A. and Walker, I. (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncology, 5, 497-508.
12. Bulina, M. E., Chudakov, D. M., Britanova, O. V., et al. (2006) A genetically encoded photosensitizer. Nat. Biotechnol., 24, 95-99.
13. Business Insights Report (2010) The Cancer Market Outlook to 2015. Business Insights Ltd.
14. Carcenac, M., Larroque, C., Langlois, R., et al. (1999). Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates. Photochem. Photobiol., 70, 930-936
15. Carcenac, M., Dorvillius, M., Garambois, V., et al. (2001) Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br. J. Cancer. 85, 1787-1793.
16. Carter, P. J. (2006). Potent antibody therapeutics by design. Nat. Rev. Immunol., 6, 343-357.
17. Castano, A. P., Mroz, P. and Hamblin, M. R. (2006). Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer, 6, 535-545.
18. Celli, J. P., Spring, B. Q., Rizvi, I., et al. (2010) Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem. Rev., 110, 2795-2838.
19. Clarke, O. J. and Boyle, R.W. (1999) Isothiocyanatoporphyrins, useful intermediates for the conjugation of porphyrins with biomolecules and solid supports. Chem. Commun., 1999, 2231-2232.
20. Dahle, J., Bagdonas, S., Kaalhus, O., et al. (2000) The bystander effect in photodynamic inactivation of cells. Biochim. Biophys. Acta, 1475, 273-280.
21. Deonarain, M. P. (2008) Recombinant antibodies for cancer therapy. Exp. Opin. Biol. Ther., 8, 1123-1141.
22. Dolmans, D. E, Fukumura D. and Jain R. K. (2003) Photodynamic therapy for cancer. Nat. Rev. Cancer, 3, 380-387.
23. Duska, L. R, Hamblin, M. R., Bamberg, M. P. and Hasan, T. (1997) Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer, 75, 837-844.
24. Duska, L. R., Hamblin, M. R., Miller, J. L. and Hasan, T. (1999) Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J. Natl Cancer Inst., 91, 1557-1563.
25. Fabbrini, M., Trachsel, E., Soldani, P., et al. (2006) Selective occlusion of tumour blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int. J. Cancer, 118, 1805-1813.
26. Fien, S. M. and Oseroff, A. R. (2007) Photodynamic therapy for non-melanoma skin cancer. J. Nat. Comp. Cancer Net., 5, 531-540.
27. Folli, S., Wagnieres, G., Pelegrin, A., et al. (1992) Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc. Nat. Acad. Sci. (USA), 89, 7973-7977.
28. Freitas, I. and Baronzio, G. F. (1991) Tumour hypoxia, reoxygenation and oxygenation strategies: possible role in photodynamic therapy. J. Photochem. Photobiol. B, 11, 3-30.
29. Frochot, C., Di Stasio, B., Vanderesse, R., et al. (2007) Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg Chem., 35, 205-220.
30. Gravier, J., Schneider, R., Frochot, C., et al. (2008) Improvement of meta-tetra(hydroxyphenyl) chlorinlike photosensitizer selectivity with folate-based targeted delivery, synthesis and in vivo delivery studies. J. Med. Chem., 51, 3867-3877.
31. Hamblin, M. R. (2008) Advances in photodynamic therapy: basic, translational and clinical, in Engineering in Medicine and Biology Series. (eds M.R. Hamblin and P. Mroz) Artech House, Norwood, MA, USA, p. 559.
32. Hamblin, M. R., Miller, J. L. and Hasan, T. (1996) Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res., 56, 5205-5210.
33. Hasan, T., Lin, A., Yarmush, D., et al. (1989) Monoclonal antibody-chromophore conjugates as selective phototoxins. J. Contr. Rel., 10, 107-113.
34. Hemming, A. W., Davis, N. L., Dubois, B., et al. (1993) Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate. Surg. Oncol., 2, 187-196.
35. Hopper, C., Niziol, C. and Sidhu, M. (2004) The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol., 40, 372-382.
36. Hu, Z., Rao, B., Chen, S. and Duanmu, J. (2010) Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer, 10, 235-247.
37. Hudson, R., Carcenac, M., Smith, K., et al. (2005) The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br. J. Cancer, 92, 1442-1449.
38. Hughes, B. (2010) Antibody-drug conjugates for cancer: poised to deliver? Nat. Rev. Drug Discov., 9, 665-667.
39. Ichikawa, K., Hikita, T., Maeda, N., et al. (2005) Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta, 1669, 69-74.
40. Jiang, F. N., Liu, D. J., Neyndorff, H., et al. (1991) Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J. Natl Cancer Inst., 83, 1218-1225.
41. Jiang, F. N., Richter, A. M., Jain, A. K., et al. (1993) Biodistribution of a benzoporphyrin derivativemonoclonal antibody conjugate in A549-tumour-bearing nude mice. Biotechnol. Ther., 4, 43-61.
42. Josefsen, L. B. and Boyle, R. W. (2008) Photodynamic therapy: novel third-generation photosensitizers one step closer? Br. J. Pharmacol., 154, 1-3.
43. Kabingu, E., Oseroff, A. R., Wilding, G. E. and Gollnick, S. O. (2009) Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res., 15, 4460-4466.
44. Kaspar, M., Zardi, L. and Neri, D. (2006) Fibronectin as target for tumour therapy. Int. J. Cancer, 118, 1331-1339.
45. Kuimova, M. K., Bhatti, M., Deonarain, M., et al. (2007) Fluorescence characterisation of multiplyloaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem. Photobiol. Sci., 6, 933-939.
46. Kwitniewski, M., Juzeniene, A., Glosnicka, R. and Moan, J. (2008) Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem. Photobiol. Sci., 7, 1011- 1017.
47. Liu, T., Wu, L. Y., Choi, J. K. and Berkman, C. E. (2009) In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen. Prostate, 69, 585-594.
48. Lou, P. J., Jones, L. and Hopper, C. (2003) Clinical outcomes of photodynamic therapy for head-andneck cancer. Technol. Cancer Res. Treat., 2, 311-317.
49. MacDonald, I. J. and Dougherty, T. J. (2001) Basic principles of photodynamic therapy. J. Porph. Phthalocyan., 5, 105-129.
50. Mang, T. S. (2004) Lasers and light sources for PDT: past, present and future. Photodiag. Photodynam. Ther., 1, 43-48.
51. Mellish, K. J. and Brown, S. B. (2001) Verteporfin: a milestone in opthalmology and photodynamic therapy. Exp. Opin. Pharmacother., 2, 351-361.
52. Mew, D., Lum, V., Wat, C. K., et al. (1985) Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res., 45, 4380-4386.
53. Mew, D., Wat, C., Towers, G. and Levy, J. (1983) Photoimmunotherapy: treatment of animal tumours with tumour-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol., 130, 1473-1477.
54. Moore, C. M., Pendse, D. and Emberton, M. (2009) Photodynamic therapy for prostate cancer-a review of current status and future promise. Nat. Clin. Pract. Urol., 6, 18-30.
55. Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N. and Esteva, F. J. (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol., 3, 269-280.
56. Nyst, H. J., Tan, I. B., Stewart, F. A. and Balm, A. J. M. (2009) Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? Photodiag. Photodynam. Ther., 6, 3-11.
57. Oleinick, N. L., Morris, R. L. and Belichenko, I. (2002) The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci., 1, 1-21.
58. Oseroff, A. R., Ohuoha, D., Hasan, T., et al. (1986) Antibody-targeted photolysis: selective photodestruction of human T cell leukaemia cells using monoclonal antibody-chlorin e6 conjugates. Proc. Natl Acad. Sci. USA, 83, 8744-8748
59. Pini, A., Viti, F., Santucci, A., Carnemolla, B., et al. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a twodimensional gel. J. Biol. Chem., 273, 21769-21776.
60. Rancan, F., Helmreich, M., Mölich, A., et al. (2007) Intracellular uptake and phototoxicity of 3(1),3(2)- didehydrophytochlorin-fullerene hexaadducts. Photochem. Photobiol., 83, 1330-1338.
61. Robertson, C. A., Evans, D. H. and Abrahamse, H. (2009) Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B: Biology, 96, 1-8.
62. Savellano, M. D. and Hasan, T. (2003) Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol., 77, 431-439.
63. Savellano, M. D. and Hasan, T. (2005) Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin Cancer Res., 11, 1658-1668.
64. Savellano, M. D., Pogue, B. W., Hoopes, P. J., et al. (2005) Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res., 65, 6371-6379.
65. Schweitzer, V. G. and Somers, M. L. (2010) Photofrin-mediated photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx. Las. Surg. Med., 42, 1-8.
66. Sehgal, I., Sibrian-Vazquez, M. and Vicente M. G. (2008) Photoinduced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins. J. Med. Chem., 51, 6014-6020.
67. Serebrovskaya, E. O., Edelweiss, E. F., Stremovskiy, O. A., et al. (2009). Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. Proc Natl Acad. Sci. USA, 106, 9221-9225.
68. Shieh, Y. A., Yang, S. J., Wei, M. F. and Shieh, M. J. (2010) Aptamer-based tumour-targeted drug delivery for photodynamic therapy. ACS Nano. 4, 1433-1442.
69. Soukos, N. S., Hamblin, M. R., Keel, S., et al. (2001) Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res., 61, 4490-4496
70. Staneloudi, C., Smith, K. A., Hudson, R., et al. (2007) Development and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer. Immunology, 120, 512-517.
71. Steele, J. K., Liu, D., Stammers, A. T., et al. (1988) Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumour cells. Cancer Immunol. Immunother., 26, 125-131.
72. Sternberg, E. D., Dolphin, D. and Brückner, C. (1998) Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron, 54, 4151-4202.
73. Trachtenberg, J.,Weersink, R. A., Davidson, S. R., et al. (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int., 102, 556-562.
74. van Dongen, G. A. M. S., Visser, G. W. M. and Vrouenraets, M. B. (2004) Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv. Drug Del. Rev., 56, 31-52.
75. Verma, S., Watt, G. M., Mai, Z. and Hasan, T. (2007) Strategies for enhanced photodynamic therapy effects. Photochem. Photobiol., 83, 996-1005.
76. Vrouenraets, M. B., Visser, G. W. M., Stewart, F. A., et al. (1999). Development of metatetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res., 59, 1505-1513.
77. Vrouenraets, M.B., Visser, G.W., Stigter, M., et al. (2001) Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res., 61, 1970-1975.
78. Yarmush, M. L., Thorpe, W. P., Strong L., et al. (1993) Antibody-targeted photolysis. Crit. Rev. Ther. Drug Carriers, 10, 197-252.
79. Yemul, S., Berger, C., Estabrook, A., et al. (1987) Selective killing of T lymphocytes by phototoxic liposomes. Proc. Natl Acad. Sci. USA, 84, 246-250.